Skip to main content
. 2020 Feb 11;21(3):259–267. doi: 10.3348/kjr.2019.0695

Table 3. Distribution of US-Guided 14-Gauge Core-Needle Biopsy According to Pathologic Results.

Pathologic Results 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total OR (95% CI) P
Benign 941 (72.7) 1063 (70.7) 1013 (73.6) 1250 (76.3) 1513 (76.6) 1575 (75.7) 1468 (75.8) 1497 (74.2) 1467 (74.4) 1469 (69.6) 1619 (69.4) 1320 (64.3) 16195 (72.6) 1.035 (1.032, 1.038) < 0.001
High risk 37 (2.9) 30 (2.0) 26 (1.9) 45 (2.8) 74 (3.8) 64 (3.1) 52 (2.7) 57 (2.8) 81 (4.1) 111 (5.3) 111 (4.8) 108 (5.3) 796 (3.6) 1.129 (1.112, 1.146) < 0.001
Total malignancy 316 (24.4) 411 (27.3) 338 (24.6) 344 (21.0) 388 (19.7) 441 (21.2) 418 (21.6) 465 (23.0) 424 (21.5) 531 (25.2) 604 (25.9) 626 (30.5) 5306 (23.8) 1.058 (1.05, 1.067) < 0.001
DCIS 35 (2.7) 44 (2.9) 33 (2.4) 47 (2.9) 49 (2.5) 62 (3.0) 57 (2.9) 62 (3.1) 69 (3.5) 94 (4.5) 101 (4.3) 98 (4.8) 751 (3.4) 1.107 (1.09, 1.124) < 0.001
Invasive cancer 281 (21.7) 367 (24.4) 305 (22.2) 297 (18.1) 339 (17.2) 379 (18.2) 361 (18.6) 403 (20.0) 355 (18.0) 437 (20.7) 503 (21.6) 528 (25.7) 4555 (20.4) 1.051 (1.044, 1.057) < 0.001

Values are presented as numbers of core-needle biopsies with percentages in parenthesis. OR is defined as how many times number of biopsies increased each year. DCIS = ductal carcinoma in situ